Evidence map›Paper›PMID 36239534›Full record

ArticleChannels (Austin, Tex.)2022

Association of respiratory failure with inhibition of NaV1.6 in the phrenic nerve.

Rebecca M Klein, Mark E Layton, Hillary Regan, Christopher P Regan, Yuxing Li, Tracey Filzen, Matt Cato, Michelle K Clements, Jixin Wang, Raul Sanoja and 12 more

Open access · goldAbstract read
In one paragraph

Article in Channels (Austin, Tex.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Discovery of Arylsulfonamide NaACS medicinal chemistry letters · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Rebecca M KleinMerck Research Laboratories, Merck & Co., Rahway, NJ, USA.ORCID 0000-0001-9638-3752
Mark E Layton
Hillary Regan
Christopher P Regan
Yuxing Li
Tracey Filzen
Matt Cato
Michelle K Clements
Jixin Wang
Raul Sanoja
Thomas J Greshock
Anthony J Roecker
Joseph E Pero
Ron Kim
Christopher Burgey
Christopher T John
Ying-Hong Wang
Neetesh Bhandari
Arie Struyk
Richard L Kraus
Darrell A Henze
Andrea K Houghton
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As part of a drug discovery effort to identify potent inhibitors of NaV1.7 for the treatment of pain, we observed that inhibitors produced unexpected cardiovascular and respiratory effects in vivo. Specifically, inhibitors administered to rodents produced changes in cardiovascular parameters and respiratory cessation. We sought to determine the mechanism of the in vivo adverse effects by studying the selectivity of the compounds on NaV1.5, NaV1.4, and NaV1.6 in in vitro and ex vivo assays. Inhibitors lacking sufficient NaV1.7 selectivity over NaV1.6 were associated with respiratory cessation after in vivo administration to rodents. Effects on respiratory rate in rats were consistent with effects in an ex vivo hemisected rat diaphragm model and in vitro NaV1.6 potency. Furthermore, direct blockade of the phrenic nerve signaling was observed at exposures known to cause respiratory cessation in rats. Collectively, these results support a significant role for NaV1.6 in phrenic nerve signaling and respiratory function.

Indexed as

NAV1.7 Voltage-Gated Sodium ChannelRespiratory InsufficiencyAnimalsPainPhrenic NerveRatsNAV1.7 Voltage-Gated Sodium Channelphrenic nerverespirationselectivitySodium channel inhibitor

Identifiers

PMID36239534
PMCPMC9578445
OpenAlexW4306175425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.